Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

Completed · Phase 3 · Has a placebo group

Conditions studied: Peanut Allergy

In brief

The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).

Key facts

Study ID
NCT03211247
Run by
DBV Technologies
People needed
414
Starts
2017-07-31
Expected to finish
2022-04-27
Last updated by the study team
2024-12-16

Who can join

Age: 1 and older, up to 3. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.